Vera Therapeutics Statistics
Total Valuation
VERA has a market cap or net worth of $2.66 billion. The enterprise value is $2.10 billion.
Important Dates
The next estimated earnings date is Wednesday, May 6, 2026, before market open.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
VERA has 71.71 million shares outstanding. The number of shares has increased by 16.10% in one year.
| Current Share Class | 71.71M |
| Shares Outstanding | 71.71M |
| Shares Change (YoY) | +16.10% |
| Shares Change (QoQ) | +2.79% |
| Owned by Insiders (%) | 0.92% |
| Owned by Institutions (%) | 85.09% |
| Float | 51.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.39 |
| P/TBV Ratio | 4.53 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.64, with a Debt / Equity ratio of 0.13.
| Current Ratio | 13.64 |
| Quick Ratio | 13.43 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -41.89 |
Financial Efficiency
Return on equity (ROE) is -50.71% and return on invested capital (ROIC) is -30.02%.
| Return on Equity (ROE) | -50.71% |
| Return on Assets (ROA) | -28.36% |
| Return on Invested Capital (ROIC) | -30.02% |
| Return on Capital Employed (ROCE) | -46.31% |
| Weighted Average Cost of Capital (WACC) | 10.59% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.20M |
| Employee Count | 249 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, VERA has paid $1,000 in taxes.
| Income Tax | 1,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +59.82% in the last 52 weeks. The beta is 1.17, so VERA's price volatility has been higher than the market average.
| Beta (5Y) | 1.17 |
| 52-Week Price Change | +59.82% |
| 50-Day Moving Average | 40.68 |
| 200-Day Moving Average | 34.84 |
| Relative Strength Index (RSI) | 35.52 |
| Average Volume (20 Days) | 1,271,128 |
Short Selling Information
The latest short interest is 9.87 million, so 13.77% of the outstanding shares have been sold short.
| Short Interest | 9.87M |
| Short Previous Month | 9.76M |
| Short % of Shares Out | 13.77% |
| Short % of Float | 19.06% |
| Short Ratio (days to cover) | 7.35 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -315.47M |
| Pretax Income | -299.61M |
| Net Income | -299.62M |
| EBITDA | -315.01M |
| EBIT | -315.47M |
| Earnings Per Share (EPS) | -$4.66 |
Full Income StatementBalance Sheet
The company has $714.59 million in cash and $77.31 million in debt, giving a net cash position of $637.28 million or $8.89 per share.
| Cash & Cash Equivalents | 714.59M |
| Total Debt | 77.31M |
| Net Cash | 637.28M |
| Net Cash Per Share | $8.89 |
| Equity (Book Value) | 604.52M |
| Book Value Per Share | 8.48 |
| Working Capital | 675.43M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$241.10 million and capital expenditures -$630,000, giving a free cash flow of -$241.73 million.
| Operating Cash Flow | -241.10M |
| Capital Expenditures | -630,000 |
| Depreciation & Amortization | 468,000 |
| Net Borrowing | 23.34M |
| Free Cash Flow | -241.73M |
| FCF Per Share | -$3.37 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |